68 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
7 Nov 23
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
to and in support of the approval of a New Drug Application or applicable foreign regulatory approval; the COVID-19 pandemic may disrupt our business
8-K
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic and other geopolitical events may disrupt Crinetics’ business
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
property rights, and it may be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic and other geopolitical events may disrupt
8-K
EX-99.1
c3fs dpl8rtvd1z
8 Aug 23
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:01am
8-K
EX-99.1
8ebj3877nus8hs1syko
4 May 23
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
8-K
q62rrk
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am
8-K
EX-99.1
wy68 25xsj0hj94d4p0
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am
8-K
EX-99.1
rrmk1 fam
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
60y3y
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
EX-99.1
2gcw4sx2lig81 8u1xo
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
EX-99.1
92en9347 7gse6a0p8
3 Oct 22
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
8:30am
8-K
EX-99.1
tra9kuv69y7zt56u
12 Aug 22
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:41am